{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:44:29Z","timestamp":1786977869694,"version":"build-2736575974"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatol Commun"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:p>\n                    The identification of patients with advanced fibrosis who do not need any further hepatocellular carcinoma (HCC) surveillance after the eradication of hepatitis C is pivotal. In this study, we developed a simple serum\u2010based risk model that could identify patients with low\u2010risk HCC. This was a nationwide multicenter study involving 16 Hospitals in Japan. Patients with advanced fibrosis (1,325 in a derivation cohort and 508 in a validation cohort) who achieved sustained virological responses at 24\u00a0weeks after treatment (SVR24) were enrolled. The HCC risk model at any point after SVR24 and its change were evaluated, and subsequent HCC development was analyzed. Based on the multivariable analysis, patients fulfilling all of the factors (GAF4 criteria: gamma\u2010glutamyl transferase\u00a0&lt;\u00a028\u00a0IU\/L, alpha\u2010fetoprotein\u00a0&lt;\u00a04.0\u00a0ng\/mL, and Fibrosis\u20104 Index\u00a0&lt;\u00a04.28) were classified as low\u2010risk and others were classified as high\u2010risk. When patients were stratified at the SVR24, and 1\u00a0year, and 2\u00a0years after SVR24, subsequent HCC development was significantly lower in low\u2010risk patients (0.5\u20101.1 per 100 person\u2010years in the derivation cohort and 0.9\u20101.1 per 100 person\u2010years in the validation cohort) than in high\u2010risk patients at each point. HCC risk from 1\u00a0year after SVR24 decreased in patients whose risk improved from high\u2010risk to low\u2010risk (HCC incidence: 0.6 per 100 person\u2010years [hazard ratio (HR)\u00a0=\u00a00.163 in the derivation cohort] and 1.3 per 100 person\u2010years [HR\u00a0=\u00a00.239 in the validation cohort]) than in those with sustained high risk.\n                    <jats:italic toggle=\"yes\">Conclusion:<\/jats:italic>\n                    The HCC risk model based on simple serum markers at any point after SVR and its change can identify patients with advanced fibrosis who are at low HCC risk, and these patients may be able to reduce HCC surveillance.\n                  <\/jats:p>","DOI":"10.1002\/hep4.1833","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T03:09:36Z","timestamp":1634872176000},"page":"461-472","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus"],"prefix":"10.1097","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4634-6616","authenticated-orcid":false,"given":"Nobuharu","family":"Tamaki","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology,Musashino Red Cross Hospital,Tokyo,Japan"},{"name":"NAFLD Research Center,Division of Gastroenterology and Hepatology,Department of Medicine,University of California San Diego,La Jolla,California,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Kurosaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology,Musashino Red Cross Hospital,Tokyo,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Yasui","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology,Musashino Red Cross Hospital,Tokyo,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nami","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology,Hiroshima Red Cross Hospital and Atomic\u2010bomb Survivors Hospital,Hiroshima,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology,Hiroshima Red Cross Hospital and Atomic\u2010bomb Survivors Hospital,Hiroshima,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitomi","family":"Hasebe","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology,Japanese Red Cross Asahikawa Hospital,Asahikawa,Hokkaido,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouji","family":"Joko","sequence":"additional","affiliation":[{"name":"Center for Liver\u2010Biliary\u2010Pancreatic Disease,Matsuyama Red Cross Hospital,Matsuyama,Ehime,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Akahane","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology,Japanese Red Cross Ishinomaki Hospital,Ishinomaki,Miyagi,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Furuta","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology,Masuda Red Cross Hospital,Masuda,Shimane,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Kobashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology,Japanese Red Cross Okayama Hospital,Okayama,Okayama,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology,Japanese Red Cross Kyoto Daiichi Hospital,Kyoto,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Yagisawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology,Japanese Red Cross Akita Hospital,Akita,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Marusawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology,Osaka Red Cross Hospital,Osaka,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology,Japanese Red Cross Otsu Hospital,Otsu,Shiga,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Kojima","sequence":"additional","affiliation":[{"name":"Department of Hepatology,Japanese Red Cross Ise Hospital,Ise,Mie,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology,Japanese Red Cross Medical Center,Tokyo,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology,Matsue Red Cross Hospital,Matsue,Shimane,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine,Japanese Red Cross Society Himeji Hospital,Himeji,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine,Japanese Red Cross Society Himeji Hospital,Himeji,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology,Ogaki Municipal Hospital,Ogaki,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Toyoda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology,Ogaki Municipal Hospital,Ogaki,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-9991","authenticated-orcid":false,"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[{"name":"NAFLD Research Center,Division of Gastroenterology and Hepatology,Department of Medicine,University of California San Diego,La Jolla,California,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namiki","family":"Izumi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology,Musashino Red Cross Hospital,Tokyo,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,10,22]]},"reference":[{"key":"hep41833-bib-0001-20241115","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","article-title":"Natural history of hepatitis C","volume":"61","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"hep41833-bib-0002-20241115","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"hep41833-bib-0003-20241115","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"hep41833-bib-0004-20241115","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/hepr.13246","article-title":"Real\u2010world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: a nationwide multicenter study by the Japanese Red Cross Liver Study Group","volume":"49","year":"2019","journal-title":"Hepatol Res"},{"key":"hep41833-bib-0005-20241115","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/hepr.13362","article-title":"Real\u2010world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): a nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group","volume":"49","year":"2019","journal-title":"Hepatol Res"},{"key":"hep41833-bib-0006-20241115","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/hepr.13546","article-title":"Twelve weeks of ledipasvir\/sofosbuvir all\u2010oral regimen for patients with chronic hepatitis C genotype 2 infection: integrated analysis of three clinical trials","volume":"50","year":"2020","journal-title":"Hepatol Res"},{"key":"hep41833-bib-0007-20241115","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/hepr.13328","article-title":"Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: results from a multicenter, real\u2010world cohort study","volume":"49","year":"2019","journal-title":"Hepatol Res"},{"key":"hep41833-bib-0008-20241115","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/hepr.13503","article-title":"Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update","volume":"50","year":"2020","journal-title":"Hepatol Res"},{"key":"hep41833-bib-0009-20241115","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/j.gastro.2018.04.008","article-title":"Incidence of hepatocellular carcinoma in patients with HCV\u2010associated cirrhosis treated with direct\u2010acting antiviral agents","volume":"155","year":"2018","journal-title":"Gastroenterology"},{"key":"hep41833-bib-0010-20241115","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/hep.26442","article-title":"\u03b1\u2010fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C","volume":"58","year":"2013","journal-title":"Hepatology"},{"key":"hep41833-bib-0011-20241115","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1111\/hepr.13554","article-title":"Impact of viral eradication by direct\u2010acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus\u2010related compensated cirrhosis patients","volume":"50","year":"2020","journal-title":"Hepatol Res"},{"key":"hep41833-bib-0012-20241115","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/hepr.13512","article-title":"Long\u2010term prognosis of liver disease in patients with eradicated chronic hepatitis C virus: an analysis using a Markov chain model","volume":"50","year":"2020","journal-title":"Hepatol Res"},{"key":"hep41833-bib-0013-20241115","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/hepr.13501","article-title":"JSH guidelines for the management of hepatitis C virus infection, 2019 update; protective effect of antiviral therapy against hepatocarcinogenesis","volume":"50","year":"2020","journal-title":"Hepatol Res"},{"key":"hep41833-bib-0014-20241115","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.cgh.2018.12.018","article-title":"Cost effectiveness of hepatocellular carcinoma surveillance after a sustained virologic response to therapy in patients with hepatitis C virus infection and advanced fibrosis","volume":"17","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep41833-bib-0015-20241115","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/hepr.13310","article-title":"Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic response","volume":"49","year":"2019","journal-title":"Hepatol Res"},{"key":"hep41833-bib-0016-20241115","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jhep.2020.10.016","article-title":"HCC surveillance after SVR in patients with F3\/F4 fibrosis","volume":"74","year":"2021","journal-title":"J Hepatol"},{"key":"hep41833-bib-0017-20241115","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/hepr.13233","article-title":"Wisteria floribunda agglutinin\u2010positive Mac\u20102 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct\u2010acting antivirals for hepatitis C virus","volume":"48","year":"2018","journal-title":"Hepatol Res"},{"key":"hep41833-bib-0018-20241115","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.3390\/ijms21103640","article-title":"Wisteria floribunda agglutinin\u2010positive Mac\u20102 binding protein but not \u03b1\u2010fetoprotein as a long\u2010term hepatocellular carcinoma predictor","volume":"21","year":"2020","journal-title":"Int J Mol Sci"},{"key":"hep41833-bib-0019-20241115","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.30823","article-title":"Long\u2010term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents","volume":"71","year":"2020","journal-title":"Hepatology"},{"key":"hep41833-bib-0020-20241115","article-title":"Change in Fibrosis 4 Index as predictor of high risk of incident hepatocellular carcinoma after eradication of hepatitis C virus","year":"2021","journal-title":"Clin Infect Dis"},{"key":"hep41833-bib-0021-20241115","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","year":"2006","journal-title":"Hepatology"},{"key":"hep41833-bib-0022-20241115","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s00535-013-0914-y","article-title":"Non\u2010invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients","volume":"49","year":"2014","journal-title":"J Gastroenterol"},{"key":"hep41833-bib-0023-20241115","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases","volume":"68","year":"2018","journal-title":"Hepatology"},{"key":"hep41833-bib-0024-20241115","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/hepr.13411","article-title":"Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 (4th JSH\u2010HCC guidelines) 2019 update","volume":"49","year":"2019","journal-title":"Hepatol Res"},{"key":"hep41833-bib-0025-20241115","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy\u2010to\u2010use software \u2018EZR\u2019 for medical statistics","volume":"48","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"hep41833-bib-0026-20241115","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1111\/liv.13927","article-title":"Impact of hepatocellular carcinoma aetiology and liver function on the benefit of surveillance: a novel approach for the adjustment of lead\u2010time bias","volume":"38","year":"2018","journal-title":"Liver Int"},{"key":"hep41833-bib-0027-20241115","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/hepr.12613","article-title":"Characteristics and prognosis of hepatocellular carcinoma detected in patients with chronic hepatitis C after the eradication of hepatitis C virus: a multicenter study from Japan","volume":"46","year":"2016","journal-title":"Hepatol Res"},{"key":"hep41833-bib-0028-20241115","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.31588","article-title":"A model based on noninvasive markers predicts very low hepatocellular carcinoma risk after viral response in hepatitis C virus\u2010advanced fibrosis","volume":"72","year":"2020","journal-title":"Hepatology"},{"key":"hep41833-bib-0029-20241115","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12072-019-09939-2","article-title":"Direct\u2010acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study","volume":"13","year":"2019","journal-title":"Hepatol Int"},{"key":"hep41833-bib-0030-20241115","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.cgh.2018.10.038","article-title":"Factors associated with increased risk of de novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct\u2010acting antivirals for HCV infection","volume":"17","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep41833-bib-0031-20241115","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.jhep.2020.05.052","article-title":"Personalized surveillance for hepatocellular carcinoma in cirrhosis\u2014using machine learning adapted to HCV status","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"hep41833-bib-0032-20241115","article-title":"Elastin fiber accumulation in liver correlates with the development of hepatocellular carcinoma","volume":"11","year":"2016","journal-title":"PLoS One"},{"key":"hep41833-bib-0033-20241115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/hepr.13286","article-title":"Non\u2010invasive liver fibrosis assessment correlates with collagen and elastic fiber quantity in patients with hepatitis C virus infection","volume":"49","year":"2019","journal-title":"Hepatol Res"},{"key":"hep41833-bib-0034-20241115","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.cgh.2018.11.046","article-title":"Prediction of hepatocellular carcinoma after sustained virological responses using magnetic resonance elastography","volume":"17","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep41833-bib-0035-20241115","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/jvh.13103","article-title":"Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct\u2010acting antivirals","volume":"26","year":"2019","journal-title":"J Viral Hepat"},{"key":"hep41833-bib-0036-20241115","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1002\/jmv.26490","article-title":"Changes of liver stiffness measured by magnetic resonance elastography during direct\u2010acting antivirals treatment in patients with chronic hepatitis C","volume":"93","year":"2021","journal-title":"J Med Virol"},{"key":"hep41833-bib-0037-20241115","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cgh.2017.04.038","article-title":"Magnitude and kinetics of decrease in liver stiffness after antiviral therapy in patients with chronic hepatitis C: a systematic review and meta\u2010analysis","volume":"16","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep41833-bib-0038-20241115","first-page":"E82","article-title":"Wisteria floribunda agglutinin positive human Mac\u20102\u2010binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients","volume":"45","year":"2015","journal-title":"Hepatol Res"},{"key":"hep41833-bib-0039-20241115","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3343\/alm.2021.41.1.16","article-title":"Clinical utility of Mac\u20102 binding protein glycosylation isomer in chronic liver diseases","volume":"41","year":"2021","journal-title":"Ann Lab Med"},{"key":"hep41833-bib-0040-20241115","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jhep.2019.10.005","article-title":"Non\u2010invasive prediction of liver\u2010related events in patients with HCV\u2010associated compensated advanced chronic liver disease after oral antivirals","volume":"72","year":"2020","journal-title":"J Hepatol"},{"key":"hep41833-bib-0041-20241115","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/hep.23425","article-title":"Pitfalls of liver stiffness measurement: a 5\u2010year prospective study of 13,369 examinations","volume":"51","year":"2010","journal-title":"Hepatology"},{"key":"hep41833-bib-0042-20241115","doi-asserted-by":"crossref","first-page":"10109","DOI":"10.1038\/s41598-019-46172-1","article-title":"Wisteria floribunda agglutinin\u2010positive mac\u20102 binding protein as an age\u2010independent fibrosis marker in nonalcoholic fatty liver disease","volume":"9","year":"2019","journal-title":"Sci Rep"},{"key":"hep41833-bib-0043-20241115","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/hep.23691","article-title":"Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection","volume":"52","year":"2010","journal-title":"Hepatology"},{"key":"hep41833-bib-0044-20241115","first-page":"5356498","article-title":"The dose\u2010response relationship between gamma\u2010glutamyl transferase and risk of diabetes mellitus using publicly available data: a longitudinal study in Japan","volume":"2020","year":"2020","journal-title":"Int J Endocrinol"}],"container-title":["Hepatology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep4.1833","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep4.1833","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.1833","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T05:01:03Z","timestamp":1731646863000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.1833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,22]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1002\/hep4.1833","relation":{},"ISSN":["2471-254X","2471-254X"],"issn-type":[{"value":"2471-254X","type":"print"},{"value":"2471-254X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,22]]}}}